ReActiv8®
-
Neuro
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System™
MRI clearances received in connection with certification of conformity with EU and UK Medical Device Regulations DUBLIN, July 9, 2024–(BUSINESS…
Read More » -
Neuro
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System™
U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans DUBLIN, February 12, 2024–(BUSINESS WIRE)–Mainstay Medical Holdings plc today…
Read More » -
Neuro
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States
Randomized controlled clinical trial expected to validate effectiveness of ReActiv8® Restorative NeurostimulationTM vs. optimal medical management DUBLIN, August 29, 2023–(BUSINESS WIRE)–Mainstay Medical…
Read More » -
Spine
Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom
Further real-world evidence supporting the efficacy and use of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain…
Read More » -
Neuro
Mainstay Medical announces the release of post-marketing data from the ongoing ReActiv8®-C study in patients with chronic low back pain
New real-world findings support the effectiveness and use of ReActiv8® Restorative Neurostimulation™ to treat intractable chronic low back pain November…
Read More » -
Neuro
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data continue to show compelling efficacy and safety, including improvement on all key measures of pain and disability, as compared…
Read More » -
Spine
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data shows compelling efficacy and safety, as well as improvement on all key measures of pain and disability as compared…
Read More » -
Neuro
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia
March 8, 2021 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the commercial launch in Australia of…
Read More » -
Neuro
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
June 22, 2020 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug…
Read More »